These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 25312725)

  • 1. Novel anti-inflammatory interleukin-35 as an emerging target for antiatherosclerotic therapy.
    Bobryshev YV; Sobenin IA; Orekhov AN; Chistiakov DA
    Curr Pharm Des; 2015; 21(9):1147-51. PubMed ID: 25312725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-22: a potential therapeutic target in atherosclerosis.
    Luo JW; Hu Y; Liu J; Yang H; Huang P
    Mol Med; 2021 Aug; 27(1):88. PubMed ID: 34388961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
    Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
    Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pleiotropic role of interleukin-17 in atherosclerosis.
    Allam G; Abdel-Moneim A; Gaber AM
    Biomed Pharmacother; 2018 Oct; 106():1412-1418. PubMed ID: 30119214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of interleukin 35 in atherosclerosis.
    Lin J; Kakkar V; Lu X
    Curr Pharm Des; 2015; 21(35):5151-9. PubMed ID: 26530251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles.
    Taleb S; Tedgui A; Mallat Z
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):258-64. PubMed ID: 25234818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response.
    Chistiakov DA; Sobenin IA; Orekhov AN
    Immunol Lett; 2013 Mar; 151(1-2):10-22. PubMed ID: 23411158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275.
    Reddy M; Davis C; Wong J; Marsters P; Pendley C; Prabhakar U
    Cell Immunol; 2007 May; 247(1):1-11. PubMed ID: 17761156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-23: A New Atherosclerosis Target.
    Liu W; Chang C; Hu H; Yang H
    J Interferon Cytokine Res; 2018 Oct; 38(10):440-444. PubMed ID: 30328797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances on CD4
    Grönberg C; Nilsson J; Wigren M
    Eur J Pharmacol; 2017 Dec; 816():58-66. PubMed ID: 28457923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The biological function and significance of IL-35 in the pathogenesis of atherosclerosis].
    Staciwa M; Broncel M
    Pol Merkur Lekarski; 2018 Apr; 44(262):161-164. PubMed ID: 29775441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation factor XII induces pro-inflammatory cytokine responses in macrophages and promotes atherosclerosis in mice.
    Vorlova S; Koch M; Manthey HD; Cochain C; Busch M; Chaudhari SM; Stegner D; Yepes M; Lorenz K; Nolte MW; Nieswandt B; Zernecke A
    Thromb Haemost; 2017 Jan; 117(1):176-187. PubMed ID: 27786338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Immunobiology of Interleukin-35 and Its Regulation and Gene Expression.
    Song M; Ma X
    Adv Exp Med Biol; 2016; 941():213-225. PubMed ID: 27734415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-35: a potential target for the treatment of atherosclerosis.
    Huang Y; Lin YZ; Shi Y; Ji QW
    Pharmazie; 2013 Oct; 68(10):793-5. PubMed ID: 24273881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating atherosclerosis with regulatory T cells.
    Foks AC; Lichtman AH; Kuiper J
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):280-7. PubMed ID: 25414253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-32α Inhibits Endothelial Inflammation, Vascular Smooth Muscle Cell Activation, and Atherosclerosis by Upregulating Timp3 and Reck through suppressing microRNA-205 Biogenesis.
    Son DJ; Jung YY; Seo YS; Park H; Lee DH; Kim S; Roh YS; Han SB; Yoon DY; Hong JT
    Theranostics; 2017; 7(8):2186-2203. PubMed ID: 28740544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.
    Tyagi AM; Mansoori MN; Srivastava K; Khan MP; Kureel J; Dixit M; Shukla P; Trivedi R; Chattopadhyay N; Singh D
    J Bone Miner Res; 2014 Sep; 29(9):1981-92. PubMed ID: 24677326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a role of interleukin-32 in atherosclerosis.
    Heinhuis B; Popa CD; van Tits BL; Kim SH; Zeeuwen PL; van den Berg WB; van der Meer JW; van der Vliet JA; Stalenhoef AF; Dinarello CA; Netea MG; Joosten LA
    Cytokine; 2013 Oct; 64(1):433-40. PubMed ID: 23727326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine networking of innate immunity cells: a potential target of therapy.
    Striz I; Brabcova E; Kolesar L; Sekerkova A
    Clin Sci (Lond); 2014 May; 126(9):593-612. PubMed ID: 24450743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-35: Expanding Its Job Profile.
    Sawant DV; Hamilton K; Vignali DA
    J Interferon Cytokine Res; 2015 Jul; 35(7):499-512. PubMed ID: 25919641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.